Header and Body 2

Problem Addressed

Emerging genome techniques now allow for more precise modification, therefore creating new possibilities for gene therapy. Currently, the main barrier of genome editing constructs from research settings to clinical trials is their safe and effective delivery to targeted tissues. An example of a delivery vehicle of choice for gene editing material is viral vectors. However, the complexity of their production, limited packaging capability, and limited immunogenicity restrict their application in gene therapy. The current technology employs a delivery vehicle using an HPV derived capsid that allows for increased payload size while reducing the complexity and cost of production.